Feature | April 02, 2009

WATCHMAN Device May Offer Alternative to Blood-Thinners, Lowers Stroke Risk in AF Patients

April 2, 2009 - A device implanted in the heart using minimally invasive techniques may replace the most widely prescribed drug for stroke prevention in patients with nonvalvular atrial fibrillation, according to research presented during the i2 Summit at the American College of Cardiology’s 58th annual scientific session in Orlando earlier this week.

In the Embolic Protection in Patients with Atrial Fibrillation (PROTECT AF) trial, researchers compared the current standard of therapy, anticoagulation with warfarin, to a fabric-covered expandable nitinol cage known as the WATCHMAN, which blocks blood clots that typically form in the left atrial appendage (LAA), an outpouching of the left atrium. They found that the WATCHMAN reduced by some 30 percent the combined risk of cardiovascular death and stroke (both ischemic – the type caused by a blood clot – and hemorrhagic – the type caused by excessive bleeding into the brain).

“Patients with atrial fibrillation have a six-fold increased risk of stroke and therefore require long-term anticoagulation therapy,” said David R. Holmes, Jr., M.D., Scripps professor of medicine at the Mayo Graduate School of Medicine, Rochester, MN. “The placement of this device results in excellent long-term outcomes – effective ischemic stroke prevention with the elimination of hemorrhagic strokes and major bleeding often associated with the use of warfarin.”

Atrial fibrillation is a common heart rhythm disorder that causes the upper chamber of the heart to quiver rather than squeeze blood out with each beat. When blood is allowed to pool in the atrium, it can form clots. Anticoagulation with warfarin has been proven effective for the prevention of clot-related strokes in atrial fibrillation, but it is used conservatively, largely because it can cause serious bleeding in some patients. It also necessitates regular blood tests and may require that patients restrict certain physical activities.

To implant the WATCHMAN, an interventional cardiologist guides the device into the heart through a catheter inserted in a vein in the upper leg. The catheter is threaded first into the right atrium, then into the left atrium through a puncture in the wall separating the two upper chambers of the heart. Once the catheter is positioned in the opening of LAA, the WATCHMAN is released and left permanently in place to block the formation and release of blood clots.

For the PROTECT AF study, 707 patients with nonvalvular atrial fibrillation were randomly assigned to closure of the LAA with the WATCHMAN device (463 patients), followed by discontinuation of warfarin, or to long-term treatment with warfarin (244 patients). The study found in over 900 patient-years of follow-up that the combined rate of stroke (ischemic and hemorrhagic) and cardiovascular death – the primary measures of effectiveness – was 3.4 per 100 patient-years in the device group vs. 5 per 100 patient-years in the warfarin group, a reduction of 32 percent (relative risk [RR], 0.68).

As for the safety of the device, the researchers observed more procedure-related complications in patients treated with the device (8.7 vs. 4.2 per 100 patient-years; RR, 2.08). Most complications were related to device implantation. However, after successful implantation of the WATCHMAN and discontinuation of warfarin therapy, complication rates were significantly lower with device therapy (1.7 vs. 4.2 per 100 patient-years; RR, 0.40).

The researchers concluded that the WATCHMAN is an effective alternative to warfarin therapy for preventing stroke in patients with atrial fibrillation.

“The take-home message is that although there are complications associated with implantation of the device, patients can avoid the need for chronic warfarin therapy, with all its attendant risks,” Holmes said.

Dr. Holmes presented the study at ACC under the title “Randomized Prospective Trial of Percutaneous Left Atrial Appendage Closure versus Warfarin for Stroke Prevention in Atrial Fibrillation (PROTECT AF)” at 8:30 a.m. March 28.

For more information: www.atritech.net, www.acc.org

Related Content

CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Results from a new study suggest that small molecules known as microRNAs may be part of the path
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Findings from a small...
Overlay Init